Across TCGA pan-cancer cohorts, RAB11B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RAB11B data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RAB11B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAB11B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where RAB11B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.926	0.524	.005	17	view →
LUAD	OS	Tertile	All	1.000	0.704	.026	4	view →
GBM	DFS	Quartile	All	0.242	0.445	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RAB11B tumor-vs-normal RNA expression · all RAB11B data types